KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Receivables (2016 - 2025)

Historic Receivables for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $6.7 billion.

  • Gilead Sciences' Receivables rose 4020.12% to $6.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 billion, marking a year-over-year increase of 4020.12%. This contributed to the annual value of $5.6 billion for FY2024, which is 1714.47% up from last year.
  • Latest data reveals that Gilead Sciences reported Receivables of $6.7 billion as of Q3 2025, which was up 4020.12% from $5.9 billion recorded in Q2 2025.
  • In the past 5 years, Gilead Sciences' Receivables ranged from a high of $6.7 billion in Q3 2025 and a low of $3.9 billion during Q1 2022
  • Its 5-year average for Receivables is $5.2 billion, with a median of $5.2 billion in 2022.
  • In the last 5 years, Gilead Sciences' Receivables skyrocketed by 5234.54% in 2021 and then plummeted by 1831.54% in 2022.
  • Gilead Sciences' Receivables (Quarter) stood at $5.5 billion in 2021, then grew by 3.36% to $5.6 billion in 2022, then decreased by 15.23% to $4.8 billion in 2023, then grew by 17.14% to $5.6 billion in 2024, then increased by 19.53% to $6.7 billion in 2025.
  • Its Receivables stands at $6.7 billion for Q3 2025, versus $5.9 billion for Q2 2025 and $5.6 billion for Q1 2025.